#328 RXs for Orexins? The efficacy and safety of orexin antagonists for insomnia

Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
- 7 systematic reviews of randomized, controlled trials (RCTs).1-7 Focusing on the most recent and comprehensive. Results statistically significant unless indicated.
- Systematic review1 (13 RCTs, 7875 patients, mean age ~55 years) over ~1-3 months:
- Sleep diary outcomes; compared to placebo, orexin antagonists changed:
- Sleep onset: ~9 minutes faster [example: Baseline 65 minutes, 47 minutes with orexins versus 56 minutes (placebo)].
- Total sleep time: Increased ~19 minutes.
- Time awake after falling asleep: ~9 minutes less.
- Sleep quality: Improved ~5% (example improved 0.2 points on a 4-point scale, not likely clinically meaningful).8
- No clinical difference: Awakenings or feeling refreshed on awakening.
- Other reviews2-6 found similar.
- Response on insomnia score:6 55% versus 42% (placebo), NNT=8.
- One RCT with 12 months follow-up found similar.9
- Adverse events:
- Stopping due to adverse effects: No difference.2,3,7
- Most common adverse events:1
- Somnolence 8.3% versus 2.2% (placebo), number needed to harm (NNH)=16.
- Fatigue, dry mouth, abnormal dreams each ~2-3% versus 1% placebo.
- Effects on falls unclear (4 small observational studies in hospitals): Range from associated with increased fall risk to decreased.10-13
- One observational study suggests fracture risk similar between suvorexant and z-drugs.14
- Sleep diary outcomes; compared to placebo, orexin antagonists changed:
- RCT comparing 5 and 10mg Lemborexant to Zolpidem ER:15
- Sleep onset: Lemborexant ~6 minutes better.
- Time awake after falling asleep: Range from no difference to zolpidem ~15 minutes better.
- Proportion of time asleep: No difference
- Dropout due to adverse events: 0.9% versus 2.7% zolpidem.
- Limitations
- RCTs industry sponsored, use of run-ins, incomplete outcome reporting.
- Similar efficacy16 in those >65.
- Limited evidence suggests minimal withdrawal symptoms.2,13,15,17
- Abuse potential not formally assessed in insomnia RCTs.
- Orexin inhibitors have been associated with sleep paralysis/complex sleep behaviors (example “sleep-driving”).18
- Non-pharmacologic sleep restriction therapy is effective.19
- Lemborexant (available in Canada) price: $48/30 tablets.20
Helpful review on relatively new med
8.3% somnolence could be an issue
These drugs may not be very useful
good new data
Non pharmacological treatment should be emphasized .
One of my pts felt adverse effects and self stopped this medication .
This information has been helpful
going thru this, its difficult to decide whether such small benefits outweighs the risks of getting side effects
Doesn’t seem like the effect is worth the potential side effects. Potential for abuse is my main concern so would like to know more about that.